Astellas earmarks $354.2M for Irish build; Samsung Biologics get into ADCs; Rentschler gets UK facility approved
Welcome to our new look for manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls, and more.
This week, we take a look at Samsung Biologics’ new deal with Korean biotech AimedBio as well as Rentschler Pharma’s move into the UK. Also, we zero in on the US government’s funding into NTx for RNA manufacturing and South Korea and Serbia’s new vaccine manufacturing deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.